Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus

Vaccine

Volumn 32, Issue 44, 2014, Pages 5866-5874

  Lee, Jong Seok ^a   Kwon, Young Man ^a   Hwang, Hye Suk ^a   Lee, Yu Na ^a   Ko, Eun Ju ^a   Yoo, Si Eun ^a   Kim, Min Chul ^a,b   Kim, Ki Hye ^a   Cho, Min Kyoung ^a   Lee, Young Tae ^a   Lee, You Ri ^a   Quan, Fu Shi ^c   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

Author keywords

Protection; RSV; Vaccines; VLPs

Indexed keywords

DNA VACCINE; FORMALDEHYDE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS LIKE PARTICLE VACCINE; CYTOKINE; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; G GLYCOPROTEIN, RESPIRATORY SYNCYTIAL VIRUS; IMMUNOGLOBULIN G; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; BACULOVIRUS; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; EOSINOPHIL; HISTOPATHOLOGY; IMMUNOGENICITY; MOUSE; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TH2 CELL; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS REPLICATION; WEIGHT REDUCTION; ANIMAL; ANTIBODY PRODUCTION; BACULOVIRIDAE; BAGG ALBINO MOUSE; BLOOD; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; LUNG; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BACULOVIRIDAE; CYTOKINES; IMMUNOGLOBULIN G; LUNG; MICE, INBRED BALB C; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; TH2 CELLS; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, VIRUS-LIKE PARTICLE; VIRAL FUSION PROTEINS; VIRAL LOAD;

EID: 84908071751     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.08.045     Document Type: Article

References (50)

1. Collins P.L., Melero J.A. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011, 162(Dec (1-2)):80-99.
2. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969, Apr (89)(4):435-448.
3. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89(Apr (4)):405-421.
4. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89(Apr (4)):422-434.
5. Connors M., Giese N.A., Kulkarni A.B., Firestone C.Y., Morse H.C., Murphy B.R. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994, 68(Aug (8)):5321-5325.
6. Openshaw P.J., Culley F.J., Olszewska W. Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 2001, 20(Oct 15 (Suppl 1)):S27-S31.
7. van Drunen Littel-van den Hurk S., Mapletoft J.W., Arsic N., Kovacs-Nolan J. Immunopathology of RSV infection: prospects for developing vaccines without this complication. Rev Med Virol 2007, 17(Jan-Feb (1)):5-34.
8. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
9. Li X., Sambhara S., Li C.X., Ewasyshyn M., Parrington M., Caterini J., et al. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med 1998, 188(Aug 17 (4)):681-688.
10. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., Taylor G.D.N.A. encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J Gen Virol 2000, 81(Oct (Pt 10)):2519-2523.
11. Murawski M.R., McGinnes L.W., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol 2010, 84(Jan (2)):1110-1123.
12. McGinnes L.W., Gravel K.A., Finberg R.W., Kurt-Jones E.A., Massare M.J., Smith G., et al. Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol 2011, 85(Jan (1)):366-377.
13. Schmidt M.R., McGinnes L.W., Kenward S.A., Willems K.N., Woodland R.T., Morrison T.G. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 2012, 86(Nov (21)):11654-11662.
14. Quan F.S., Kim Y., Lee S., Yi H., Kang S.M., Bozja J., et al. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice. J Infect Dis 2011, 204(Oct (7)):987-995.
15. Martinez X., Li X., Kovarik J., Klein M., Lambert P.H., Siegrist C.A. Combining DNA and protein vaccines for early life immunization against respiratory syncytial virus in mice. Eur J Immunol 1999, 29(Oct (10)):3390-3400.
16. Kohlmann R., Schwannecke S., Tippler B., Ternette N., Temchura V.V., Tenbusch M., et al. Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol 2009, 83(Dec (23)):12601-12610.
17. Ternette N., Tippler B., Uberla K., Grunwald T. Immunogenicity and efficacy of codon optimized DNA vaccines encoding the F-protein of respiratory syncytial virus. Vaccine 2007, 25(Oct (41)):7271-7279.
18. Stokes K.L., Currier M.G., Sakamoto K., Lee S., Collins P.L., Plemper R.K., et al. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 2013, 87(Sep (18)):10070-10082.
19. Kwon Y.M., Hwang H.S., Lee J.S., Ko E.J., Yoo S.E., Kim M.C., et al. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res 2014, 104(Apr):1-6.
20. Prince G.A., Curtis S.J., Yim K.C., Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 2001, 82(Dec (Pt 12)):2881-2888.
21. Shcherbo D., Shemiakina I.I., Ryabova A.V., Luker K.E., Schmidt B.T., Souslova E.A., et al. Near-infrared fluorescent proteins. Nat Methods 2010, 7(Oct (10)):827-829.
22. Hotard A.L., Shaikh F.Y., Lee S., Yan D., Teng M.N., Plemper R.K., et al. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis. Virology 2012, 434(Dec (1)):129-136.
23. Kim M.C., Song J.M., O.E.Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21(Feb (2)):485-492.
24. Song J.M., Kim Y.C., Barlow P.G., Hossain M.J., Park K.M., Donis R.O., et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antiviral Res 2010, 88(Nov (2)):244-247.
25. Jiang S., Borthwick N.J., Morrison P., Gao G.F., Steward M.W. Virus-specific CTL responses induced by an H-2K(d)-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. J Gen Virol 2002, 83(Feb (Pt 2)):429-438.
26. Olson M.R., Varga S.M. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines 2008, 7(Oct (8)):1239-1255.
27. Mok H., Lee S., Utley T.J., Shepherd B.E., Polosukhin V.V., Collier M.L., et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007, 81(Dec (24)):13710-13722.
28. Loebbermann J., Durant L., Thornton H., Johansson C., Openshaw P.J. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci USA 2013, 110(Feb (8)):2987-2992.
29. Johnson T.R., Teng M.N., Collins P.L., Graham B.S. Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 2004, 78(Jun (11)):6024-6032.
30. Stevens W.W., Kim T.S., Pujanauski L.M., Hao X., Braciale T.J. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J Immunol Methods 2007, 327(Oct (1-2)):63-74.
31. Kim S., Joo D.H., Lee J.B., Shim B.S., Cheon I.S., Jang J.E., et al. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLoS One 2012, 7(2):e32226.
32. Vaughan K., Rhodes G.H., Gershwin L.J. DNA immunization against respiratory syncytial virus (RSV) in infant rhesus monkeys. Vaccine 2005, 23(Apr (22)):2928-2942.
33. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70(May (5)):2852-2860.
34. Prince G.A., Jenson A.B., Hemming V.G., Murphy B.R., Walsh E.E., Horswood R.L., et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol 1986, 57(Mar (3)):721-728.
35. Kamphuis T., Meijerhof T., Stegmann T., Lederhofer J., Wilschut J., de Haan A. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice. PLoS One 2012, 7(5):e36812.
36. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196(Sep (6)):859-865.
37. Shaw C.A., Galarneau J.R., Bowenkamp K.E., Swanson K.A., Palmer G.A., Palladino G., et al. The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease. Vaccine 2013, 31(Jan (2)):306-312.
38. Hancock G.E., Heers K.M., Smith J.D., Scheuer C.A., Ibraghimov A.R., Pryharski K.S. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 2001, 19(Sep (32)):4874-4882.
39. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 1990, 8(Oct (5)):497-502.
40. Connors M., Collins P.L., Firestone C.Y., Sotnikov A.V., Waitze A., Davis A.R., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 1992, 10(7):475-484.
41. Castilow E.M., Olson M.R., Meyerholz D.K., Varga S.M. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J Virol 2008, 82(Mar (5)):2196-2207.
42. Bot A., Bona C. Genetic immunization of neonates. Microbes Infect/Institut Pasteur 2002, 4(Apr (4)):511-520.
43. Tree J.A., Bembridge G., Hou S., Taylor G., Fashola-Stone E., Melero J., et al. An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung. Vaccine 2004, 22(Jun (19)):2438-2443.
44. Li X., Sambhara S., Li C.X., Ettorre L., Switzer I., Cates G., et al. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology 2000, 269(Mar (1)):54-65.
45. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J Virol 1999, 73(Sep (9)):7099-7107.
46. Xu J., Ding Y., Yang Y. Enhancement of mucosal and cellular immune response in mice by vaccination with respiratory syncytial virus DNA encapsulated with transfersome. Viral Immunol 2008, 21(Dec (4)):483-489.
47. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40(Sep (1)):86-97.
48. Ye L., Wen Z., Dong K., Pan L., Bu Z., Compans R.W., et al. Immunization with a mixture of HIV Env DNA and VLP vaccines augments induction of CD8 T cell responses. J Biomed Biotechnol 2010, 2010:497219.
49. Smith G., Raghunandan R., Wu Y., Liu Y., Massare M., Nathan M., et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012, 7(11):e50852.
50. Song J.M., Hossain J., Yoo D.G., Lipatov A.S., Davis C.T., Quan F.S., et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 2010, 405(Sep 15 (1)):165-175.